Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
Brett King, Amy McMichael, Rodney Sinclair...
https://pubmed.ncbi.nlm.nih.gov/41083802/Actively Recruiting
Led by Pfizer · Updated on 2026-10-20
674
Participants Needed
148
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.
CONDITIONS
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ritlecitinib 50 mg | Ritlecitinib 100 mg | Placebo | FDA‑approved JAK inhibitors (current care) |
|---|---|---|---|---|
| What it is | An investigational oral Janus kinase inhibitor taken as a 50 mg capsule daily | An investigational oral Janus kinase inhibitor taken as a 100 mg capsule daily | A matching placebo capsule used as the control arm | FDA‑approved oral JAK inhibitors are standard treatment for severe alopecia areata |
| Role in trial | One of the active dose arms being tested | One of the active dose arms being tested | Control arm receiving placebo capsules | Represents treatment typically used outside of trials |
| Primary use | To evaluate efficacy and safety in achieving hair regrowth (SALT ≤20) | To evaluate efficacy and safety in achieving hair regrowth (SALT ≤20) | Serves as control to measure placebo response in SALT ≤20 outcome | Used in routine care to attempt hair regrowth in severe alopecia areata |
| Administration | Oral capsule taken daily | Oral capsule taken daily | Matching oral capsule taken daily | Oral JAK inhibitors taken daily as per prescribing information |
| Evidence status | Efficacy under evaluation in this phase 3 randomized trial | Efficacy under evaluation in this phase 3 randomized trial | Placebo response being measured as control benchmark | Real‑world and clinical evidence support efficacy in reducing hair loss severity |
| Important risks | Risk profile under assessment in trial; risks include infections and laboratory abnormalities | Risk profile under assessment in trial; risks include infections and laboratory abnormalities | Safety profile being assessed likewise | Approved JAK inhibitors carry warnings for infections and lab monitoring |
| Important limitations | Effectiveness and safety data not yet published; results pending | Effectiveness and safety data not yet published; results pending | Placebo responses may not reflect real‑world practice | Broad clinical evidence, but specific head‑to‑head comparison with ritlecitinib pending |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Up to 1 visit
Duration - Up to 48 weeks
Participants take ritlecitinib capsules orally once daily, either 50 mg or 100 mg depending on their assigned group. Some participants may have their dose adjusted after 24 weeks based on their response.
Up to 9 visits
Duration - Up to 4 weeks after treatment
Participants undergo safety and health assessments including physical exams, blood tests, hearing tests, chest X-rays, ECGs, scalp and eye photographs (Part 1 only), and questionnaires about alopecia areata.
1 visit
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Brett King, Amy McMichael, Rodney Sinclair...
https://pubmed.ncbi.nlm.nih.gov/41083802/Pfizer
Lead Sponsor